Table 2 Summary of the results for efficacy outcomes based on disease status
From: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
Outcomes | Group | HR or RR and 95%CI | P value | Heterogeneity (%) | P value for heterogeneity |
|---|---|---|---|---|---|
OS | Previous untreated | 0.82 (0.71–0.95) | 0.008 | 29.9 | 0.180 |
Relapsed or refractory | 0.85 (0.75–0.97) | 0.016 | 0.0 | 0.471 | |
EFS | Previous untreated | 0.76 (0.63–0.92) | 0.005 | 72.8 | < 0.001 |
Relapsed or refractory | 0.77 (0.58–1.04) | 0.084 | 83.1 | < 0.001 | |
ORR | Previous untreated | 1.00 (0.96–1.05) | 0.869 | 73.5 | < 0.001 |
Relapsed or refractory | 1.11 (0.91–1.34) | 0.302 | 65.5 | 0.013 |